5:17 PM
 | 
Jul 30, 2013
 |  BC Extra  |  Top Story

Cubist to acquire Trius, Optimer

Cubist Pharmaceuticals Inc. (NASDAQ:CBST) announced late Tuesday that it is acquiring two other infectious disease companies in cash and contingent value right (CVR) deals worth up to a total of $1.6 billion. Cubist is acquiring partner Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) for up to $801 million and Trius Therapeutics Inc. (NASDAQ:TSRX) for up to $818 million. Both deals have been approved by the boards of...

Read the full 314 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >